Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 2
2022 1
2023 1
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2024 May;14(4_suppl):690S-714S. doi: 10.1177/21925682241245615. Global Spine J. 2024. PMID: 38726630 Free PMC article. No abstract available.
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Müller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, Patti F, Grammond P, Buzzard K, Skibina O, Prat A, Girard M, Grand'Maison F, Alroughani R, Lechner-Scott J, Spitaleri D, Barnett M, Cartechini E, Sa MJ, Gerlach O, van der Walt A, Butzkueven H, Prevost J, Castillo-Triviño T, Yamout B, Khoury SJ, Yaldizli Ö, Derfuss T, Granziera C, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group. Müller J, et al. CNS Drugs. 2025 Apr;39(4):403-416. doi: 10.1007/s40263-025-01164-w. Epub 2025 Feb 14. CNS Drugs. 2025. PMID: 39953338 Free PMC article.
Persistent progression independent of relapse activity in multiple sclerosis.
Zhu C, Zhou Z, Kalincik T, Roos I, Buzzard K, Skibina O, Alroughani R, Kuhle J, Girard M, Grammond P, Lechner-Scott J, Gerlach O, John N, McCombe P, Macdonell R, van Pesch V, Laureys G, Prevost J, Horakova D, Kubala Havrdova E, Castillo-Triviño T, Ramo-Tello C, Blanco Y, Meca-Lallana JE, Lugaresi A, Tomassini V, Cartechini E, Amato MP, Spitaleri D, Patti F, Maimone D, Foschi M, Surcinelli A, D'Amico E, Yamout B, Khoury SJ, Jose Sa M, Boz C, Ozakbas S, Weinstock-Guttman B, Merlo D, Monif M, Jokubaitis VG, van der Walt A, Butzkueven H. Zhu C, et al. Brain Commun. 2025 Aug 21;7(5):fcaf306. doi: 10.1093/braincomms/fcaf306. eCollection 2025. Brain Commun. 2025. PMID: 40909095 Free PMC article.
Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance study.
Riegger J, Egberts KM, Clement HW, Schneider-Momm K, Taurines R, Fekete S, Wewetzer C, Karwautz A, Correll CU, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Banaschewski T, Hellenschmidt T, Kaess M, Kölch M, Renner T, Rexroth C, Schulte-Körne G, Walitza S, Gerlach M, Romanos M, Fleischhaker C. Riegger J, et al. J Neural Transm (Vienna). 2025 Feb;132(2):295-312. doi: 10.1007/s00702-024-02819-6. Epub 2024 Nov 2. J Neural Transm (Vienna). 2025. PMID: 39487894 Free PMC article.
Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial.
Frey M, Smigielski L, Tini E, Fekete S, Fleischhaker C, Wewetzer C, Karwautz A, Correll CU, Gerlach M, Taurines R, Plener PL, Malzahn U, Kornbichler S, Weninger L, Brockhaus M, Reuter-Dang SY, Reitzle K, Rock H, Imgart H, Heuschmann P, Unterecker S, Briegel W, Banaschewski T, Fegert JM, Hellenschmidt T, Kaess M, Kölch M, Renner T, Rexroth C, Walitza S, Schulte-Körne G, Romanos M, Egberts KM. Frey M, et al. Pharmaceutics. 2023 Aug 25;15(9):2202. doi: 10.3390/pharmaceutics15092202. Pharmaceutics. 2023. PMID: 37765171 Free PMC article.
Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice.
Egberts KM, Gerlach M, Correll CU, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Häge A, Hellenschmidt T, Imgart H, Kaess M, Karwautz A, Kölch M, Reitzle K, Renner T, Reuter-Dang SY, Rexroth C, Schulte-Körne G, Theisen FM, Walitza S, Wewetzer C, Fekete S, Taurines R, Romanos M. Egberts KM, et al. Pharmacopsychiatry. 2022 Sep;55(5):255-265. doi: 10.1055/a-1716-1856. Epub 2022 Feb 7. Pharmacopsychiatry. 2022. PMID: 35130562 Free PMC article.